Negative in Ames, in vitro human lymphocyte chromosomal aberration and in vivo rat micronucleus assays
“Fx-1006A was negative for genotoxicity in an in vitro bacterial reverse mutation assay, an in vitro chromosomal aberration assay in human lymphocytes, and an in vivo rat micronucleus assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Carcinogenicity
26-week rasH2 mouse and 2-year rat: no drug-related tumors
“Carcinogenicity were evaluated in Tg.rasH2 transgenic mice dosed at 10, 30, or 90 mg/kg/day for 26 weeks and in Sprague Dawley rats dosed at 3, 10 or 30 mg/kg/day for 2 years. Both studies were considered adequate and found to be negative for increases in tumor findings with the Executive CAC’s concurrence.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Reproductive & developmental
Rat PPND: reduced offspring survival and weight, delayed male sexual maturity, impaired learning and memory at 15 mg/kg/day
“Reduced survival, birth weight, postweaning body weight, delayed male sexual maturity, and impaired learning and memory were observed in the offspring of dams dosed at 15 mg/kg/day.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Safety pharmacology
No effects on CNS, cardiovascular or pulmonary systems in core GLP battery
“In the core GLP battery of safety pharmacology studies, tafamidis meglumine had no effects on the central nervous, cardiovascular, and pulmonary systems.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative